FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including an anti-HER2 antibody-drug conjugate (variants), a pharmaceutical composition for the treatment of HER2-expressing cancer, including the above-mentioned anti-HER2 antibody-drug conjugate, a method of treating HER2-expressing cancer, including the administration of an effective amount of anti- HER2 antibody-drug conjugate, and the use of an anti-HER2 antibody-drug conjugate in the production of a drug for the treatment of HER2-expressing cancer. In one embodiment, the anti-HER2 antibody-drug conjugate comprises a biparatopic antibody conjugated to an auristatin analog via a linker and with a low average drug to antibody ratio.
EFFECT: invention expands the arsenal of anti-HER2 agents.
36 cl, 18 dwg, 28 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIGEN-BINDING CONSTRUCTS AGAINST HER2 | 2014 |
|
RU2737882C2 |
| SITE-SPECIFIC HER2 ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2745565C2 |
| BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | 2020 |
|
RU2832083C2 |
| SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION BY GLYCOENGINEERING | 2014 |
|
RU2831409C2 |
| ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | 2016 |
|
RU2757815C2 |
| CONJUGATES OF BINDER AND ACTIVE SUBSTANCE (ADC) HAVING ENZYMATICALLY CLEAVABLE GROUPS | 2017 |
|
RU2761390C2 |
| METHODS FOR PREPARING ANTIBODY-DRUG CONJUGATE COMPOSITIONS | 2015 |
|
RU2741470C2 |
| ANTIBODY-STING AGONIST CONJUGATES AND USE THEREOF IN IMMUNOTHERAPY | 2020 |
|
RU2826228C2 |
| ANTIBODY-DRUG CONJUGATES BASED ON ERIBULIN AND APPLICATION METHODS | 2017 |
|
RU2754369C2 |
| ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF | 2020 |
|
RU2831838C2 |
